Disruption of the refill of patients’ regular combination inhaled corticosteroid therapy brand may have impacted symptoms and disease control and potentially lead to an increased rate of costly exacerbations and hospitalizations in COPD and asthma patients.
[maxbutton id=”1″ url=”http://info.rtmagazine.com/regform” text=”SUBSCRIBE TO NEWS” ]
A retrospective pharmacy analysis was conducted on 44,832 patients from age 12 and older who had Medicare Part D coverage in 2016 and 2017 and received budesonide/formoterol fixed dose combination (Symbicort) as their inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA) medication in 2016. Each of these patients were followed through Dec. 31, 2017, to observe ICS/LABA switches, changes in controller medications and use of acute medications like oral corticosteroids, antibiotics and rescue inhalers.
About half (49%) of patients within the study attempted to fill a Symbicort prescription at a pharmacy after the formulary block on Jan. 1, 2017.
Of the patients who attempted to fill the respiratory medication:
- Only 46% were approved for more than one refill of Symbicort, and 52% had their refill rejected.
- Of the patients who were rejected a refill, 37% switched to another ICS/LABA fixed dose combination, 27% of stopped their controller medication, 10% received monotherapy, 10% received triple therapy and 16% received other controller combinations.
- Of the patients who did not switch to an alternate controller medication, 37% filled a prescription for an acute medication.
- Overall, a third of the 44,832 patients did fill any controller medication post-block, 12% switched to monotherapy and 17% had no inhaled medication fills.
“This Medicare Part D formulary switch was associated with a disruption in the management of patients’ respiratory conditions,” said Dr Katie Devane, lead researcher. “Approximately 45% of the patients did not receive an ICS/LABA after the formulary block, which may have impacted patients’ symptoms and disease control and potentially lead to an increased rate of costly exacerbations and hospitalizations.”